AI Summary
This study compares the effectiveness of apixaban and aspirin in preventing adverse outcomes in patients with a history of cancer and cryptogenic stroke, as part of the ARCADIA trial. The goal is to determine which medication is more beneficial for this specific patient population.
This secondary analysis of the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial compares apixaban vs aspirin for the prevention of adverse clinical outcomes in patients with history of cancer and cryptogenic stroke.